为了探讨5-甲基胞嘧啶(5-methylcytosine,m5C)相关基因在三阴性乳腺癌(triple negative breast cancer,TNBC)患者治疗及预后中的潜在价值,构建了基于m5C相关基因的预后预测模型,用于评估TNBC患者的预后和生存状况。从基因表达总库(gene ...为了探讨5-甲基胞嘧啶(5-methylcytosine,m5C)相关基因在三阴性乳腺癌(triple negative breast cancer,TNBC)患者治疗及预后中的潜在价值,构建了基于m5C相关基因的预后预测模型,用于评估TNBC患者的预后和生存状况。从基因表达总库(gene expression omnibus,GEO)数据库和癌症基因组图谱(the cancer genome atlas,TCGA)数据库中下载TNBC基因表达谱和相应的临床数据。通过Pearson分析确定了99个m5C相关基因,进一步采用单因素Cox分析鉴定出5个与预后有关的m5C相关基因(SLC6A14、BCL11A、UGT8、LMO4、PSAT1)并构建了风险评分(risk score)预测模型,根据风险评分中位值将患者划分为高风险组和低风险组。使用Kaplan-Meier(K-M)生存分析、受试者工作特征(receiver operating characteristic,ROC)曲线、多变量Cox回归分析、构建列线图和校准曲线评估了模型的预测效能。训练集和验证集的K-M生存曲线、受试者工作特征曲线下面积(area under the curve,AUC)分析均验证了模型具有良好的预测能力。多变量Cox回归分析显示,风险评分可作为独立的预后生物标志物。使用ssGSEA、免疫评分分析和化疗药物对高低风险组患者的半最大抑制浓度(half maximal inhibitory concentration,IC50)值差异分析显示,免疫细胞和免疫检查点基因以及大多数化疗药物的IC50值在不同风险组之间的表达存在显著差异。研究结果构建了基于5个m5C相关基因的风险评分预后预测模型,这将有助于阐明TNBC中m5C相关基因的作用机制,进而提供更有价值的预后及诊断的生物标志物和潜在的治疗靶点,为TNBC患者临床个性化治疗提供理论指导。展开更多
To construct the bi-valent genetic engineering vaccine against pseudorabies virus（PRV）and porcine reproductive and respiratory syndrome virus（PRRSV）,the modified PRRSV ORF5 gene（ORF5M） and the VP22 gene of bovin...To construct the bi-valent genetic engineering vaccine against pseudorabies virus（PRV）and porcine reproductive and respiratory syndrome virus（PRRSV）,the modified PRRSV ORF5 gene（ORF5M） and the VP22 gene of bovine herpesvirus 1（BHV-1）,which encodes VP22 protein and has been demonstrated to exhibit the unusual protein transduction property,were inserted into a PRV universal transfer vector pIECMV by turns.A recombinant virus transfer vector pIECMV-VP22ORF5M possessing VP22-ORF5M fusion gene was generated.The recombinant virus transfer vector pIECMV-VP22ORF5M co-transfected the IBRS-2 cells with PRV TK-/gE-/LacZ+ genomic DNA digested by EcoRⅠusing liposome method.Based on homologous recombination,the recombinant virus was generated and then purified by the plaque assay and PCR amplification.After three rounds of plaque purification,the recombinant virus was further confirmed by PCR,Southern blot and Western blot.A recombinant PRV（rPRV）TK-/gE-/VP22GP5+ expressing VP22-GP5 fusion protein was constructed.The results of TCID50 tests showed that the insertion of the foreign genes had no influence on the propagation of rPRV in IBRS-2 or PK-15 cells.The construction of rPRV TK-/gE-/VP22GP5+ provides a basis for further study of bi-valent genetic engineering vaccines against PRRSV and PRV,and that this strategy may also be useful to develop more efficient genetic engineering vaccines against other pathogens.展开更多
文摘为了探讨5-甲基胞嘧啶(5-methylcytosine,m5C)相关基因在三阴性乳腺癌(triple negative breast cancer,TNBC)患者治疗及预后中的潜在价值,构建了基于m5C相关基因的预后预测模型,用于评估TNBC患者的预后和生存状况。从基因表达总库(gene expression omnibus,GEO)数据库和癌症基因组图谱(the cancer genome atlas,TCGA)数据库中下载TNBC基因表达谱和相应的临床数据。通过Pearson分析确定了99个m5C相关基因,进一步采用单因素Cox分析鉴定出5个与预后有关的m5C相关基因(SLC6A14、BCL11A、UGT8、LMO4、PSAT1)并构建了风险评分(risk score)预测模型,根据风险评分中位值将患者划分为高风险组和低风险组。使用Kaplan-Meier(K-M)生存分析、受试者工作特征(receiver operating characteristic,ROC)曲线、多变量Cox回归分析、构建列线图和校准曲线评估了模型的预测效能。训练集和验证集的K-M生存曲线、受试者工作特征曲线下面积(area under the curve,AUC)分析均验证了模型具有良好的预测能力。多变量Cox回归分析显示,风险评分可作为独立的预后生物标志物。使用ssGSEA、免疫评分分析和化疗药物对高低风险组患者的半最大抑制浓度(half maximal inhibitory concentration,IC50)值差异分析显示,免疫细胞和免疫检查点基因以及大多数化疗药物的IC50值在不同风险组之间的表达存在显著差异。研究结果构建了基于5个m5C相关基因的风险评分预后预测模型,这将有助于阐明TNBC中m5C相关基因的作用机制,进而提供更有价值的预后及诊断的生物标志物和潜在的治疗靶点,为TNBC患者临床个性化治疗提供理论指导。
文摘To construct the bi-valent genetic engineering vaccine against pseudorabies virus（PRV）and porcine reproductive and respiratory syndrome virus（PRRSV）,the modified PRRSV ORF5 gene（ORF5M） and the VP22 gene of bovine herpesvirus 1（BHV-1）,which encodes VP22 protein and has been demonstrated to exhibit the unusual protein transduction property,were inserted into a PRV universal transfer vector pIECMV by turns.A recombinant virus transfer vector pIECMV-VP22ORF5M possessing VP22-ORF5M fusion gene was generated.The recombinant virus transfer vector pIECMV-VP22ORF5M co-transfected the IBRS-2 cells with PRV TK-/gE-/LacZ+ genomic DNA digested by EcoRⅠusing liposome method.Based on homologous recombination,the recombinant virus was generated and then purified by the plaque assay and PCR amplification.After three rounds of plaque purification,the recombinant virus was further confirmed by PCR,Southern blot and Western blot.A recombinant PRV（rPRV）TK-/gE-/VP22GP5+ expressing VP22-GP5 fusion protein was constructed.The results of TCID50 tests showed that the insertion of the foreign genes had no influence on the propagation of rPRV in IBRS-2 or PK-15 cells.The construction of rPRV TK-/gE-/VP22GP5+ provides a basis for further study of bi-valent genetic engineering vaccines against PRRSV and PRV,and that this strategy may also be useful to develop more efficient genetic engineering vaccines against other pathogens.
